Clinical trials: Oligoastrocytoma
Malignant Glioma, Glioblastoma Multiforme
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00024570
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma Multiforme, Anaplastic Astrocytoma
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
In this study an investigational replication-defective, recombinant adenovirus expressing the interferon-beta gene (BG00001) will be directly injected into tumors, in patients with recurrent Grade III and Grade IV Gliomas, in…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
- Trial name
- NCT00031083
- Testing
- Interferon-beta
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Biogen
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
This phase I/II trial studies the side effects and best dose of vorinostat and to see how well it works when given together with radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
- Trial name
- NCT01189266
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 180 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Oligoastrocytoma, Glioblastoma
A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme
This study was to explore the effectiveness and safety of early TMZ chemotherapy between surgery and chemoradiotherapy plus the standard concomitant radiochemotherapy regimen.
- Trial name
- NCT05600491
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Recurrent High-grade Glioma, Grade III Astrocytoma
Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma
This is a Phase I study of ex vivo expanded CD34+ hematopoietic stem cells (exHSCs) plus nivolumab in pediatric patients with histologically confirmed diagnosis of a non-brainstem high-grade glioma (NB-HGG, WHO Grade III or IV…
- Conditions
- Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma
- Trial name
- Peds CHAMP1ON (NCT07031765)
- Testing
- exHSC, Nivolumab, Resection or biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Low-Grade Glioma, Recurrent Low-Grade Glioma
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
- Conditions
- Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
- Trial name
- NCT04923126
- Testing
- Mirdametinib
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- St. Jude Children's Research Hospital
Glioblastoma, Gliosarcoma
Sorafenib in Newly Diagnosed High Grade Glioma
This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination with Temodar and radiation therapy in patients with newly diagnosed high grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
- Trial name
- NCT00884416
- Testing
- Sorafenib dose escalation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Geneva
Malignant Glioma, Glioblastoma Multiforme
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
- Trial name
- NCT00024557
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Glioblastoma, Gliosarcoma
A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
This is a Phase I study of Nanoliposomal CPT-11 in patients with Recurrent high-grade gliomas. Patients must have a histologically proven intracranial malignant glioma, which includes glioblastoma multiforme (GBM), gliosarcoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00734682
- Testing
- Nanoliposomal CPT-11
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Astrocytoma, Oligodendroglioma
A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
Low grade gliomas (LGGs) are the most common primary central nervous system malignancies. Brain surgeries with the most possible extent of resection are endeavored to achieve longer survivals in LGG patients.
- Conditions
- Astrocytoma, Oligodendroglioma, Oligoastrocytoma
- Trial name
- NCT02209428
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Huashan Hospital
Oligodendroglioma, Astrocytoma, Grade II
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
This is a pilot neoadjuvant vaccine study in adults with WHO grade II glioma, for which surgical resection of the tumor is clinically indicated.
- Conditions
- Oligodendroglioma, Astrocytoma, Grade II, Glioma, Astrocytic, Glioma
- Trial name
- NCT02549833
- Testing
- GBM6-AD and poly-ICLC before and after surgery, GBM6-AD and poly-ICLC after surgery only
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jennie Taylor
Brain Cancer, Glioblastoma Multiforme
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase I Objectives: -To determine the maximum tolerated dose (MTD) of vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide in adult patients with recurrent glioblastoma multiforme (GBM) and anaplastic gliomas.
- Trial name
- NCT01110876
- Testing
- Vorinostat, Erlotinib, Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Gliomas
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
The goal of this clinical research study is to find the highest tolerable dose of lenalidomide combined with Camptosar (irinotecan) as well as to see if this drug combination can help control malignant gliomas.
- Trial name
- NCT00671801
- Testing
- Irinotecan, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblatoma, Gliosarcoma
Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols
The objective of this study is to evaluate patients with tumors of the central nervous system (CNS) for eligibility in the National Cancer Institute s research studies.
- Conditions
- Glioblatoma, Gliosarcoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT00035373
- Where
- United States
- Volunteers
- 767 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas
This is a single-center, open-label, non-randomized, Phase I/IIa study to investigate the safety, tolerability, and antitumor efficacy of AXL1717 (picropodophyllin as active agent formulated in an oral suspension; PPP) in…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- AXL1717 (NCT01721577)
- Testing
- AXL1717
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Rush University Medical Center
Glioblastoma Multiforme, Anaplastic Astrocytoma
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
This Phase 1 study in patients with newly diagnosed malignant glioma is designed to determine the highest dose of IL13-PE38QQR that can be safely administered by Convection Enhanced Delivery (CED) to the area around the tumor…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma
- Trial name
- NCT00089427
- Testing
- IL13-PE38QQR, Surgery for placement, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- INSYS Therapeutics Inc
Low Grade Glioma, Glioblastoma Multiforme
(11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas
Background: The blood-brain barrier helps to protect the central nervous system (brain and spinal cord) from harmful toxins, but also prevents potentially useful chemotherapy from reaching brain tumors.
- Conditions
- Low Grade Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01281982
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
The purpose of the study is to determine the safety and efficacy of intracranially implanted Carmustine in the treatment of patients with primary malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma
- Trial name
- NCT01656980
- Testing
- Carmustine, tumor resection surgery
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
Glioblastoma, Gliosarcoma
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Background: In order to survive, brain tumors must have a network of blood vessels to supply it with oxygen and nutrients. The tumors produce substances that enable new blood vessels to form.
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00667394
- Testing
- Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Central nervous system (CNS) malignancies are the second most common malignancy and the most common solid tumor of childhood, including adolescence.
- Conditions
- Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma
- Trial name
- NCT01884740
- Testing
- SIACI of Erbitux and Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Weill Medical College of Cornell University